| Literature DB >> 21261856 |
Sukhadeo Barbuddhe1, Trinad Chakraborty.
Abstract
Listeria monocytogenes is a Gram-positive bacterium that is able to survive both in the environment and to invade and multiply within eukaryotic cells. Currently L. monocytogenes represents one of the most well-studied and characterized microorganisms in bacterial pathogenesis. A hallmark of L. monocytogenes virulence is its ability to breach bodily barriers such as the intestinal epithelium, the blood-brain barrier as well as the placental barrier to cause severe systemic disease. Curiously, this theme is repeated at the level of the interaction between the individual cell and the bacterium where its virulence factors contribute to the ability of the bacteria to breach cellular barriers. L. monocytogenes is a model to study metabolic requirements of bacteria growing in an intracellular environment, modulation of signalling pathways in the infected cell and interactions with cellular defences involving innate and adaptive immunity. Technical advances such as the creation of LISTERIA-susceptible mouse strains, had added interest in the study of the natural pathogenesis of the disease via oral infection. The use of attenuated strains of L. monocytogenes as vaccines has gained considerable interest because they can be used to express heterologous antigens as well as to somatically deliver recombinant DNA to eukaryotic cells. A novel vaccine concept, the use of non-viable but metabolically active bacteria to induced immunoprotective responses, has been developed with L. monocytogenes. In this mini-review, we review the strategies used by L. monocytogenes to subvert the cellular functions at different stages of the infection cycle in the host and examine how these properties are being exploited in biotechnological and clinical applications.Entities:
Mesh:
Substances:
Year: 2008 PMID: 21261856 PMCID: PMC3815243 DOI: 10.1111/j.1751-7915.2008.00037.x
Source DB: PubMed Journal: Microb Biotechnol ISSN: 1751-7915 Impact factor: 5.813
Figure 1Listeria monocytogenes crosses all important barriers in human body.
Figure 2Mechanisms of Listeria‐mediated entry into eukaryotic cells. Zipper mechanism: bacterial uptake is promoted from the ‘outside’ by the interaction between bacterial adhesins and host cell surface molecules. Interaction activates host cell signalling pathways that result in moderate actin cytoskeleton rearrangements. The signalling component acronyms and their translations are given in Table 2.
The signalling component acronyms and their translations involved in the mechanisms of Listeri a‐mediated entry into eukaryotic cells.
| Acronym | Translation |
|---|---|
| ARF6 | ADP‐ribosylation factor 6 |
| ARHGAP10 | Rho GTPase‐activating protein 10 |
| Arp | Actin‐related protein |
| Ena/VASP family | Enabled homologue/vasodilator‐stimulated phosphoprotein |
| F‐actin | Filamentous actin |
| G‐actin | Globular actin |
| GAG | Glucosaminoglycans |
| ABI | Abl interactor 1 |
| F‐actin | Filamentous actin |
| GAB1 | GRB2‐associated binding protein 1 |
| SHC | SRC‐homology‐2‐ domain‐containing transforming protein C |
| WAVE | Wiskott–Aldrich syndrome protein (WASP)‐family verprolin homologous protein. |
Examples of eukaryotic targets hijacked by Listeria monocytogenes.
| Event | Host target | Effector protein/ phospholipid | Mechanism hijacked |
|---|---|---|---|
| Bacterial invasion | Human E‐cadherin | InlA | Cytoskeleton dynamics linked to intercellular adherence and junction formation |
| Glycoprotein gC1qR; Met/hepatocyte growth factor receptor (HGF); glycosaminoglycans (GAGs) | InlB | Activation of HFG receptor and PI‐3‐kinase‐mediated signalling | |
| Lifestyle in cytosol | Phagolysosome | LLO | Lyses the vacuole, pore formation |
| Protein kinase C (PKC) Cascade | PI‐PLC | Promotes escape of the bacterium from a macrophage‐like cell phagosome | |
| Microsomal‐6‐phosphate transporter; translocase | hpt | Mimicry of hexose‐P intracellular growth | |
| Arp2/3 complex; actin; VASP | ActA | Promotes actin‐based motility |
The different areas of biotechnology where the knowledge on Listeria is being harnessed toward application.
| Biotechnological application | |
|---|---|
| Intracellular parasitism | Pathogenesis |
| Pathophysiology | |
| Patho‐Biotechnology | Diagnostics |
| DNA based vaccines | |
| Model for cell biologist | T‐cell responses |
| Host pathogen interactions | |
| Cellular processes | |
| Tumor Biology | Cytosolic drug delivery |
| New drug discovery | Inhibitors of intracellular replication |
| Drug delivery to target cells | hpt |
| LLO | |